---
title: "Phage therapy funding 1999–2023: rapid growth from a narrow funder base"
id: "medrxiv-2-twenty-five-years-of-phage-therapy-funding-rapid-growth-narrow-base"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-2-twenty-five-years-of-phage-therapy-funding-rapid-growth-narrow-base"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.11.06.26367455v1?rss=1"
published_at: "2026-11-09T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Phage therapy funding 1999–2023: rapid growth from a narrow funder base
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-2-twenty-five-years-of-phage-therapy-funding-rapid-growth-narrow-base
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.11.06.26367455v1?rss=1)
- **Published At:** 2026-11-09T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The authors searched **Dimensions** on 13 February 2024 and screened 1,521 grant records, then analysed 802 grants with recorded funding amounts that started between 1999 and 2023. The analysed grants summed to USD 318.6 million. - Grant counts rose at 12.2% per year; recorded funding rose at 16.6% per year (14.1% after inflation). Growth occurred from a small annual average—about USD 13 million per year across the field. - US funders provided 47.7% of recorded funding. One institute, **NIAID**, accounted for 21.0% of funding overall and 23.3% in 2016–2023. Funding concentration was high: the top 10% of recipient institutions received 53.4% of dollars. - Low- and lower-middle-income countries received 0.33% of recorded funding. Only seven grants explicitly linked Global North and Global South recipients. When counting grants (not dollars), the Global South received 17.5%, because several funders in that region report no amounts. - Topic shifts appeared: antibiotic-resistance research within phage funding rose from about 3% of funding to roughly a quarter by the end of the period. - Gender and investigator distribution signals: female-only teams received grants that were 19% smaller than male-only teams after adjustment (95% CI -32 to -2). And 84% of researchers held only a single grant. - Sensitivity analyses: the headline results were robust, holding in 37 of 40 sensitivity checks. The authors reported code, country tables and aggregate data openly on GitHub and an interactive dashboard; grant-level data cannot be redistributed under Dimensions terms. - The study team used log-linear growth models, the Herfindahl-Hirschman index and the Gini coefficient to measure concentration, latent Dirichlet allocation for topic classification, and first-name inference for team gender. The source did not report detailed per-grant methodology such as individual grant amounts by topic beyond aggregated summaries in the manuscript.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=zR_ur19fIM1KjggD2y5t1lk1DVS0sIBv46t1F75OaUY-1794250747.326985-1.2.1.1-a9KcXDMp8GUsBUGhQcQpguliv48iRhS0ebLXTLP.QIoWNgV5KYNseLKm674gFI24) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.11.06.26367455v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # Twenty-five years of phage therapy funding: rapid growth, narrow base [ View ORCID Profile](http://orcid.org/0000-0001-5581-3891)Maxime Descartes Mbogning Fonkou, Nathan Yanwou, [ View ORCID Profile](http://orcid.org/0000-0001-9031-1731)Roland Bamou, [ View ORCID Profile](http://orcid.org/0000-0001-7171-2345)Idriss Tsayem Ngueguim, [ View ORCID Profile](http://orcid.org/0000-0002-0950-2205)Abdourahamane YACOUBA doi: https://doi.org/10.64898/2026.11.06.26367455 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Maxime Descartes Mbogning Fonkou 1 CognosX, BC, Canada; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Maxime%2BDescartes%2BMbogning%2BFonkou%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Mbogning%20Fonkou%20MD&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AMaxime%2BDescartes%2BMbogning%2BFonkou%2B) * [ORCID record for Maxime Descartes Mbogning Fonkou](http://orcid.org/0000-0001-5581-3891 "Open in new tab") * For correspondence: dmbogning15@gmail.com Nathan Yanwou 2 Department of Epidemiology, Biostatistics and Occupational Health, School of Population and Global Health, McGill University, Montreal, Quebec, Canada; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Nathan%2BYanwou%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Yanwou%20N&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ANathan%2BYanwou%2B) Roland Bamou 3 Institut de Recherche de Yaounde (IRY), Organisation de Coordination pour la Lutte Contre les Endemies en Afrique Centrale (OCEAC), Yaounde P.O. Box 288, Cameroon; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Roland%2BBamou%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Bamou%20R&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ARoland%2BBamou%2B) * [ORCID record for Roland Bamou](http://orcid.org/0000-0001-9031-1731 "Open in new tab") Idriss Tsayem Ngueguim 4 Diagnostic Radiology Residency Program, Department of Radiology, University of Maryland Medical Center, Baltimore, Maryland, USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Idriss%2BTsayem%2BNgueguim%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Tsayem%20Ngueguim%20I&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AIdriss%2BTsayem%2BNgueguim%2B) * [ORCID record for Idriss Tsayem Ngueguim](http://orcid.org/0000-0001-7171-2345 "Open in new tab") Abdourahamane YACOUBA 5 Universite Abdou Moumouni/National Reference Laboratory of HIV, Tuberculosis and Antimicrobials resistance / National Hospital AB DIALLO, Lamorde, Niamey, Niger * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Abdourahamane%2BYACOUBA%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=YACOUBA%20A&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAbdourahamane%2BYACOUBA%2B) * [ORCID record for Abdourahamane YACOUBA](http://orcid.org/0000-0002-0950-2205 "Open in new tab") * [Abstract](https://www.medrxiv.org/content/10.64898/2026.11.06.26367455v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1340587/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.11.06.26367455v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1340587/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.11.06.26367455v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1340587/1) * [Supplementary material](https://www.medrxiv.org/content/10.64898/2026.11.06.26367455v1.supplementary-material)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_data/node:1340587/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.11.06.26367455v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1340587/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.11.06.26367455v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1340587/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Background. Bacteriophage therapy is moving from compassionate use toward regulated clinical use, as antimicrobial resistance (AMR) grows. Who pays for phage therapy research, and where the money goes, has not been measured globally. Methods. We searched Dimensions on 13 February 2024 and screened 1,521 grant records. We analysed the 802 grants with a recorded funding amount that started in 1999-2023 (USD 318.6 million). We estimated log-linear growth, measured concentration with the Herfindahl-Hirschman index (HHI) and Gini coefficient, and counted shared grants fractionally across recipient institutions. Topics came from latent Dirichlet allocation, and team gender from first names. Sensitivity analyses added the 272 relevant grants without an amount, merged yearly records into projects, and varied key definitions. Results. Grants grew by 12.2% a year and recorded funding by 16.6% a year (14.1% after inflation), yet the field received only about USD 13 million a year. US funders provided 47.7% of funding and one institute, NIAID, 21.0%, rising to 23.3% in 2016-2023. The top 10% of recipient institutions received 53.4%. Low- and lower-middle-income countries received 0.33% of recorded funding, and only 7 grants linked Global North and Global South recipients. Antibiotic-resistance research rose from 3% to about a quarter of funding. Female-only teams received grants 19% smaller than male-only teams after adjustment (95% CI -32 to -2), and 84% of researchers held a single grant. Counting grants rather than dollars, the Global South received 17.5%, because several of its funders report no amounts. The headline results held in 37 of 40 sensitivity checks. Conclusions. Phage therapy research funding is growing fast from a small base, but it rests on a narrow set of funders and countries and rarely reaches the countries most affected by AMR. Broader funding, and fuller reporting of national investments, will matter as phage therapy enters regulated clinical use. https://cognosx.ca/dashboards/phage-funding.html ### Competing Interest Statement The views expressed are the authors own. MDMF is the founder of CognosX, a science-intelligence company. RB, NY, AY and ITN declare no competing interests. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability All code, the country classification table, and every aggregate table and figure are openly available at https://github.com/descartesmbogning/phage-therapy-funding-complete. Grant-level data cannot be redistributed under the Dimensions terms of use; they can be rebuilt with the published query and a Dimensions subscription. Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/). bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.11.06.26367455v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.11.06.26367445v1 "Plasma phosphorylated tau species across neurodegenerative and cerebrovascular diseases: An ONDRI study")[Next ](https://www.medrxiv.org/content/10.64898/2026.11.06.26367433v1 "Polygenic Prediction of Depression Liability Reveals Broad Genetic Associations Across Development, Families, and Populations") Posted November 09, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.11.06.26367455v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/11/09/2026.11.06.26367455.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.11.06.26367455v1#p-5) [Supplementary Material ](https://www.medrxiv.org/content/10.64898/2026.11.06.26367455v1.supplementary-material) [ Data/Code](https://www.medrxiv.org/content/early/2026/11/09/2026.11.06.26367455.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) Twenty-five years of phage therapy funding: rapid growth, narrow base Maxime Descartes Mbogning Fonkou, Nathan Yanwou, Roland Bamou, Idriss Tsayem Ngueguim, Abdourahamane YACOUBA medRxiv 2026.11.06.26367455; doi: https://doi.org/10.64898/2026.11.06.26367455 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.11.06.26367455v1%26text%3DTwenty-five%2520years%2520of%2520phage%2520therapy%2520funding%253A%2520rapid%2520growth%252C%2520narrow%2520base "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.11.06.26367455v1%26t%3DTwenty-five%2520years%2520of%2520phage%2520therapy%2520funding%253A%2520rapid%2520growth%252C%2520narrow%2520base "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.11.06.26367455v1%26title%3DTwenty-five%2520years%2520of%2520phage%2520therapy%2520funding%253A%2520rapid%2520growth%252C%2520narrow%2520base%26summary%3D%26source%3DmedRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.medrxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.11.06.26367455v1%26title%3DTwenty-five%2520years%2520of%2520phage%2520therapy%2520funding%253A%2520rapid%2520growth%252C%2520narrow%2520base "Share on Mendeley") [ Citation Tools](https://www.medrxiv.org/ "Citation Tools") [ Get QR code](https://connect.medrxiv.org/qr/2026.11.06.26367455) * [Tweet Widget](http://twitter.com/share?url=https%3A//www.medrxiv.org/content/10.64898/2026.11.06.26367455v1&count=horizontal&via=&text=Twenty-five%20years%20of%20phage%20therapy%20funding%3A%20rapid%20growth%2C%20narrow%20base&counturl=www.medrxiv.org/content/10.64898/2026.11.06.26367455v1 "Tweet This") Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos **Subject Areas** [**All Articles**](https://www.medrxiv.org/content/early/recent) * [Addiction Medicine](https://www.medrxiv.org/collection/addiction-medicine) (638) * [Allergy and Immunology](https://www.medrxiv.org/collection/allergy-and-immunology) (918) * [Anesthesia](https://www.medrxiv.org/collection/anesthesia) (351) * [Cardiovascular Medicine](https://www.medrxiv.org/collection/cardiovascular-medicine) (5008) * [Dentistry and Oral Medicine](https://www.medrxiv.org/collection/dentistry-and-oral-medicine) (496) * [Dermatology](https://www.medrxiv.org/collection/dermatology) (428) * [Emergency Medicine](https://www.medrxiv.org/collection/emergency-medicine) (676) * [Endocrinology (including Diabetes Mellitus and Metabolic Disease)](https://www.medrxiv.org/collection/endocrinology-including-diabetes-mellitus-and-metabolic-disease) (1694) * [Epidemiology](https://www.medrxiv.org/collection/epidemiology) (16269) * [Forensic Medicine](https://www.medrxiv.org/collection/forensic-medicine) (36) * [Gastroenterology](https://www.medrxiv.org/collection/gastroenterology) (1241) * [Genetic and Genomic Medicine](https://www.medrxiv.org/collection/genetic-and-genomic-medicine) (7284) * [Geriatric Medicine](https://www.medrxiv.org/collection/geriatric-medicine) (752) * [Health Economics](https://www.medrxiv.org/collection/health-economics) (1093) * [Health Informatics](https://www.medrxiv.org/collection/health-informatics) (5293) * [Health Policy](https://www.medrxiv.org/collection/health-policy) (1468) * [Health Systems and Quality Improvement](https://www.medrxiv.org/collection/health-systems-and-quality-improvement) (1833) * [Hematology](https://www.medrxiv.org/collection/hematology) (599) * [HIV/AIDS](https://www.medrxiv.org/collection/hiv-aids) (1382) * [Infectious Diseases (except HIV/AIDS)](https://www.medrxiv.org/collection/infectious_diseases) (16492) * [Intensive Care and Critical Care Medicine](https://www.medrxiv.org/collection/intensive-care-and-critical-care-medicine) (1203) * [Medical Education](https://www.medrxiv.org/collection/medical-education) (700) * [Medical Ethics](https://www.medrxiv.org/collection/medical-ethics) (156) * [Nephrology](https://www.medrxiv.org/collection/nephrology) (752) * [Neurology](https://www.medrxiv.org/collection/neurology) (7601) * [Nursing](https://www.medrxiv.org/collection/nursing) (378) * [Nutrition](https://www.medrxiv.org/collection/nutrition) (1130) * [Obstetrics and Gynecology](https://www.medrxiv.org/collection/obstetrics-and-gynecology) (1296) * [Occupational and Environmental Health](https://www.medrxiv.org/collection/occupational-and-environmental-health) (1040) * [Oncology](https://www.medrxiv.org/collection/oncology) (3749) * [Ophthalmology](https://www.medrxiv.org/collection/ophthalmology) (1093) * [Orthopedics](https://www.medrxiv.org/collection/orthopedics) (410) * [Otolaryngology](https://www.medrxiv.org/collection/otolaryngology) (466) * [Pain Medicine](https://www.medrxiv.org/collection/pain-medicine) (502) * [Palliative Medicine](https://www.medrxiv.org/collection/palliative-medicine) (143) * [Pathology](https://www.medrxiv.org/collection/pathology) (721) * [Pediatrics](https://www.medrxiv.org/collection/pediatrics) (1861) * [Pharmacology and Therapeutics](https://www.medrxiv.org/collection/pharmacology-and-therapeutics) (756) * [Primary Care Research](https://www.medrxiv.org/collection/primary-care-research) (786) * [Psychiatry and Clinical Psychology](https://www.medrxiv.org/collection/psychiatry-and-clinical-psychology) (6135) * [Public and Global Health](https://www.medrxiv.org/collection/public-and-global-health) (9994) * [Radiology and Imaging](https://www.medrxiv.org/collection/radiology-and-imaging) (2533) * [Rehabilitation Medicine and Physical Therapy](https://www.medrxiv.org/collection/rehabilitation-medicine-and-physical-therapy) (1521) * [Respiratory Medicine](https://www.medrxiv.org/collection/respiratory-medicine) (1270) * [Rheumatology](https://www.medrxiv.org/collection/rheumatology) (661) * [Sexual and Reproductive Health](https://www.medrxiv.org/collection/sexual-and-reproductive-health) (804) * [Sports Medicine](https://www.medrxiv.org/collection/sports-medicine) (598) * [Surgery](https://www.medrxiv.org/collection/surgery) (804) * [Toxicology](https://www.medrxiv.org/collection/toxicology) (109) * [Transplantation](https://www.medrxiv.org/collection/transplantation) (320) * [Urology](https://www.medrxiv.org/collection/urology) (308) Evaluation/discussion of this paper x Comments 0TRiP 0Community 0Automated 0Blogs/Media 0Video 0 Comments medRxiv aims to provide a venue for anyone to comment on a medRxiv preprint. Comments are moderated for offensive or irrelevant content (this can take ~24 h). Please avoid duplicate submissions. The content of a comment is not endorsed by medRxiv. medRxiv is
## Related Clinical Research

- [Multimorbidity with tuberculosis in Kampala: prevalence, care gaps and impact on outcomes](https://medichelpline.com/clinical-feed/medrxiv-1-multimorbidity-in-tuberculosis-and-its-impact-on-health-and-treatment-outcomes.md)
- [Late-pregnancy household food insecurity associated with lower neonatal birthweight in Tigray, Eth](https://medichelpline.com/clinical-feed/plos-one-6-association-between-late-pregnancy-household-food-insecurity-and-birth-weight.md)
- [Bupropion Hydrochloride for Improving Recovery in Acute Ischaemic Stroke: BASE Trial Protocol](https://medichelpline.com/clinical-feed/bmj-open-4-protocol-for-base-a-multicentre-double-blind-randomised-controlled-trial-of.md)
- [Impact of loss to follow-up on 5-year mortality after tuberculosis treatment in São Paulo, Brazil](https://medichelpline.com/clinical-feed/plos-medicine-0-loss-to-follow-up-during-tuberculosis-treatment-and-5-year-mortality-in-brazil.md)
- [AI detection of pulmonary tuberculosis on chest X‑ray: meta-analysis of clinical cohort accuracy](https://medichelpline.com/clinical-feed/medrxiv-12-artificial-intelligence-for-pulmonary-tuberculosis-detection-on-chest-x-ray.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.